RxDoctor Payments Data

Federico Ferri, MD

Internal Medicine · Johnston, RINPI 1013903400

Payments from drug & device makers

$464in general payments, 2019–2025

Across 10 payments — averaging $46.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$142
  • Novo Nordisk$114
  • Aimmune Therapeutics, Inc.$61
  • Lilly USA, LLC$60
  • Inspire Medical Systems, Inc.$38
  • AbbVie$26
  • plus $23 from 1 others

What the payments were for

  • Food & beverage$464100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$464 in reported general payments places this provider in the 70th percentile of 808 internal medicine providers in Rhode Island.

See all internal medicine providers in Rhode Island

Medicare billing

Part B allowed, 2024
$98,523
Medicare patients
259
Services billed
1,206

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin179$174,808
EliquisApixaban161$121,485
XareltoRivaroxaban63$45,030
OzempicSemaglutide24$36,714
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$18,369
Atorvastatin Calcium1,590$16,078
Metoprolol Succinate512$8,002
Lisinopril772$6,962
Levothyroxine Sodium567$6,843
JanuviaSitagliptin Phosphate12$5,607
Losartan Potassium485$5,593
Omeprazole393$5,442
Albuterol Sulfate HfaAlbuterol Sulfate144$4,930
DexilantDexlansoprazole12$4,348
Amlodipine Besylate537$4,267

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$114$36,71424 claims
AbbVieSynthroid$26$3,36047 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 808 internal medicine providers in Rhode Island.

Other internal medicine in Johnston

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →